Bayer Adds Warning to Nimotop Label

The FDA has requested that Bayer add a boxed warning to the nimodipine (Nimotop) labeling to warn about medication administration errors with nimodipine.  Nimodipine is approved for oral administration to improve neurological outcome after subarachnoid hemorrhage. When administered intravenously or parenterally, it can cause serious adverse events, including death.  Nimodipine must not be administered intravenously or by any parenteral route.

Healthcare providers who prescribe, dispense or administer Nimodipine should administer nimodipine capsules orally only.

For patients unable to swallow a capsule, use an oral syringe to extract the gel inside the capsule. The syringe should be labeled "for oral use only." The nimodipine gel should be administered through the patient's naso-gastric tube or G-tube, followed by 30 ml normal saline solution (0.9%).

Ensure that nimodipine is never administered intravenously, or by any parenteral route. 
 
The FDA has received reports of medication administration errors in which nimodipine was given intravenously or parenterally, rather than orally.

Because cases are still occurring, FDA has asked Bayer to add a boxed warning to the nimodipine labeling to describe the life-threatening risk of parenteral administration. Additionally, FDA has requested that Bayer develop an oral solution of nimodipine for use in patients who cannot swallow a capsule.   
Nimodipine is a calcium-channel blocker, which lowers blood pressure; when the drug is administered intravenously instead of orally, the effect can be much stronger, leading to cardiovascular collapse and possibly to death.